Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the pot.
作者信息
Alvarez Carlos A, Neeland Ian J, McGuire Darren K
机构信息
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, TX, USA Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Division of Cardiology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
出版信息
Diab Vasc Dis Res. 2015 Mar;12(2):74-7. doi: 10.1177/1479164114563303.
Abstract
摘要
相似文献
1
Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the pot.钠-葡萄糖协同转运蛋白抑制剂在糖尿病治疗中的应用：增加优势
Diab Vasc Dis Res. 2015 Mar;12(2):74-7. doi: 10.1177/1479164114563303.
2
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.索格列净的研发，一种双钠依赖性葡萄糖转运蛋白1/2抑制剂。
Diab Vasc Dis Res. 2015 Mar;12(2):101-10. doi: 10.1177/1479164114563304.
3
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.探索钠-葡萄糖协同转运蛋白2（SGLT2）作为糖尿病治疗靶点：基础生理学及影响
Diab Vasc Dis Res. 2015 Mar;12(2):78-89. doi: 10.1177/1479164114561992. Epub 2015 Jan 23.
4
SGLT2 inhibitors and renal function.钠-葡萄糖协同转运蛋白2抑制剂与肾功能。
Med Lett Drugs Ther. 2016 Jul 18;58(1499):91-2.
5
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.肾钠-葡萄糖协同转运蛋白抑制在2型糖尿病管理中的应用
Am J Physiol Renal Physiol. 2015 Dec 1;309(11):F889-900. doi: 10.1152/ajprenal.00267.2015. Epub 2015 Sep 9.
6
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.钠-葡萄糖协同转运蛋白2抑制剂与心血管风险：提出的作用途径及正在进行的结局试验综述
Diab Vasc Dis Res. 2015 Mar;12(2):90-100. doi: 10.1177/1479164114559852. Epub 2015 Jan 14.
7
Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.恩格列净：2型糖尿病患者的一种新治疗选择。
Drugs Today (Barc). 2015 Sep;51(9):519-35. doi: 10.1358/dot.2015.51.9.2368554.
8
Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的肾脏保护作用：超越葡萄糖重吸收抑制
Curr Vasc Pharmacol. 2017;15(2):96-102. doi: 10.2174/1570161114666161007163426.
9
The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂对心脏代谢指标的影响：超越降糖作用
Cardiovasc Drugs Ther. 2017 Apr;31(2):215-225. doi: 10.1007/s10557-017-6724-3.
10
Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.超越糖尿：探索 SGLT₂ 抑制剂在糖尿病中的肾内作用。
Diabetes Metab. 2014 Dec;40(6 Suppl 1):S17-22. doi: 10.1016/S1262-3636(14)72691-6.
引用本文的文献
1
Effect of Cichorium intybus L. seed extract on renal parameters in experimentally induced early and late diabetes type 2 in rats.菊苣种子提取物对实验性诱导的大鼠2型早期和晚期糖尿病肾脏参数的影响。
Ren Fail. 2017 Nov;39(1):211-221. doi: 10.1080/0886022X.2016.1256317. Epub 2016 Nov 16.
本文引用的文献
1
Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012.1980 年至 2012 年美国 20 至 79 岁成年人确诊糖尿病的患病率和发病率趋势。
JAMA. 2014 Sep 24;312(12):1218-26. doi: 10.1001/jama.2014.11494.
2
A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.用于 2 型糖尿病的新型治疗药物：SGLT2 抑制剂。
Diabetes Metab J. 2014 Aug;38(4):261-73. doi: 10.4093/dmj.2014.38.4.261.
3
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.恩格列净添加至 2 型糖尿病合并慢性肾脏病患者现有降糖治疗方案的疗效和安全性：一项随机、双盲、安慰剂对照试验。
Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24.
4
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病中的疗效和安全性：一项随机临床试验的荟萃分析。
Diabetes Obes Metab. 2014 May;16(5):457-66. doi: 10.1111/dom.12244. Epub 2013 Dec 29.
5
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.在二甲双胍控制不佳的 2 型糖尿病患者中，卡格列净对比格列美脲的疗效和安全性（CANTATA-SU）：一项随机、双盲、3 期非劣效性临床试验的 52 周结果。
Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12.
6
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.依帕列净和其他钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在 2 型糖尿病治疗中的作用：临床前和临床数据。
Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4.
7
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂达格列净对吡格列酮单药治疗血糖控制不佳的 2 型糖尿病患者的 HbA1c、体重和低血糖风险的影响。
Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23.
8
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.钠-葡萄糖共转运蛋白 2（SGLT 2）抑制剂在 2 型糖尿病治疗中的作用。
Endocr Rev. 2011 Aug;32(4):515-31. doi: 10.1210/er.2010-0029. Epub 2011 May 23.
9
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.与二甲双胍相比，不同胰岛素促分泌剂在有或无既往心肌梗死的 2 型糖尿病患者中的死亡率和心血管风险：一项全国性研究。
Eur Heart J. 2011 Aug;32(15):1900-8. doi: 10.1093/eurheartj/ehr077. Epub 2011 Apr 6.
10
Glucose handling by the kidney.肾脏对葡萄糖的处理
Kidney Int Suppl. 2011 Mar(120):S1-6. doi: 10.1038/ki.2010.509.
Zotero 插件